160 related articles for article (PubMed ID: 37414748)
21. Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway.
Fu X; Liu M; Qu S; Ma J; Zhang Y; Shi T; Wen H; Yang Y; Wang S; Wang J; Nan K; Yao Y; Tian T
J Exp Clin Cancer Res; 2018 Mar; 37(1):52. PubMed ID: 29530052
[TBL] [Abstract][Full Text] [Related]
22. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
23. Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis.
Zhou L; Wang Z; Chen X; Li X; Ge C; Min X; Zhao F; Chen T; Li J
Int J Biol Sci; 2023; 19(12):3892-3907. PubMed ID: 37564208
[TBL] [Abstract][Full Text] [Related]
24. The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway.
Chen L; Liu D; Yi X; Qi L; Tian X; Sun B; Dong Q; Han Z; Li Q; Song T; Guo M; Zhang W; Guo H; Zhang T
Cell Death Dis; 2020 May; 11(5):320. PubMed ID: 32371982
[TBL] [Abstract][Full Text] [Related]
25. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract][Full Text] [Related]
26. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner.
Li H; Lan T; Xu L; Liu H; Wang J; Li J; Chen X; Huang J; Li X; Yuan K; Zeng Y; Wu H
J Exp Clin Cancer Res; 2020 Jul; 39(1):128. PubMed ID: 32631394
[TBL] [Abstract][Full Text] [Related]
27. USP22-JMJD8 axis promotes Lenvatinib resistance in hepatocellular carcinoma.
Guo J; Zhao J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119617. PubMed ID: 37898375
[TBL] [Abstract][Full Text] [Related]
28. GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.
Tiu YC; Gong L; Zhang Y; Luo J; Yang Y; Tang Y; Lee WM; Guan XY
Cancer Gene Ther; 2022 Nov; 29(11):1720-1730. PubMed ID: 35760898
[TBL] [Abstract][Full Text] [Related]
29. Piezoeletric cold atmospheric plasma induces apoptosis and autophagy in human hepatocellular carcinoma cells through blocking glycolysis and AKT/mTOR/HIF-1α pathway.
Wang Y; Mang X; Li D; Chen Y; Cai Z; Tan F
Free Radic Biol Med; 2023 Nov; 208():134-152. PubMed ID: 37543168
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis.
Deng R; Lu X; Hong C; Cai R; Wang P; Xiong L; Wang X; Chen Q; Lin J
J Transl Med; 2022 Oct; 20(1):485. PubMed ID: 36274132
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Cell Proliferation and Metastasis by Scutellarein Regulating PI3K/Akt/NF-κB Signaling through PTEN Activation in Hepatocellular Carcinoma.
Ha SE; Kim SM; Vetrivel P; Kim HH; Bhosale PB; Heo JD; Lee HJ; Kim GS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445559
[TBL] [Abstract][Full Text] [Related]
32. FOXA2 plays a critical role in hepatocellular carcinoma progression and lenvatinib-associated drug resistance.
Wang Z; Shen J; Chen C; Wen T; Li C
Biosci Trends; 2023 May; 17(2):136-147. PubMed ID: 36823043
[TBL] [Abstract][Full Text] [Related]
33. Long non-coding RNA LOC107985656 represses the proliferation of hepatocellular carcinoma cells through activation of the tumor-suppressive Hippo pathway.
Zeng Y; Xu Q; Xu N
Bioengineered; 2021 Dec; 12(1):7964-7974. PubMed ID: 34565286
[TBL] [Abstract][Full Text] [Related]
34. microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC.
Sun L; Wang L; Chen T; Yao B; Wang Y; Li Q; Yang W; Liu Z
J Cell Mol Med; 2019 Dec; 23(12):8292-8304. PubMed ID: 31576658
[TBL] [Abstract][Full Text] [Related]
35. microRNA-206 prevents hepatocellular carcinoma growth and metastasis via down-regulating CREB5 and inhibiting the PI3K/AKT signaling pathway.
Chi Y; Gong Z; Xin H; Wang Z; Liu Z
Cell Cycle; 2022 Dec; 21(24):2651-2663. PubMed ID: 36003063
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of UBE2Q1 via gene copy number gain in hepatocellular carcinoma promotes cancer progression through β-catenin-EGFR-PI3K-Akt-mTOR signaling pathway.
Zhang B; Deng C; Wang L; Zhou F; Zhang S; Kang W; Zhan P; Chen J; Shen S; Guo H; Zhang M; Wang Y; Zhang F; Zhang W; Xiao J; Kong B; Friess H; Zhuge Y; Yan H; Zou X
Mol Carcinog; 2018 Feb; 57(2):201-215. PubMed ID: 29027712
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-519a promotes tumor growth by targeting PTEN/PI3K/AKT signaling in hepatocellular carcinoma.
Tu K; Liu Z; Yao B; Han S; Yang W
Int J Oncol; 2016 Mar; 48(3):965-74. PubMed ID: 26708293
[TBL] [Abstract][Full Text] [Related]
38. HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.
Wang WM; Xu Y; Wang YH; Sun HX; Sun YF; He YF; Zhu QF; Hu B; Zhang X; Xia JL; Qiu SJ; Zhou J; Yang XR; Fan J
Oncotarget; 2017 Jul; 8(29):47121-47135. PubMed ID: 28454092
[TBL] [Abstract][Full Text] [Related]
39. Targeting ACYP1-mediated glycolysis reverses lenvatinib resistance and restricts hepatocellular carcinoma progression.
Wang S; Zhou L; Ji N; Sun C; Sun L; Sun J; Du Y; Zhang N; Li Y; Liu W; Lu W
Drug Resist Updat; 2023 Jul; 69():100976. PubMed ID: 37210811
[TBL] [Abstract][Full Text] [Related]
40. Long noncoding RNA HAGLROS promotes cell proliferation, inhibits apoptosis and enhances autophagy via regulating miR-5095/ATG12 axis in hepatocellular carcinoma cells.
Wei H; Hu J; Pu J; Tang Q; Li W; Ma R; Xu Z; Tan C; Yao T; Wu X; Long X; Wang J
Int Immunopharmacol; 2019 Aug; 73():72-80. PubMed ID: 31082725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
